Pharmacotherapeutic options for visceral leishmaniasis - Current scenario

Clinical Medicine: Pathology

Volumn 2009, Issue 2, 2009, Pages 1-4

  Pandey, Krishna ^a   Sinha, Prabhat Kumar ^a   Das, Vidyanand Ravi ^a   Bimal, Sanjiva ^a   Singh, Shubhankar K ^a   Das, Pradeep ^a  

^a RAJENDRA MEMORIAL RESEARCH INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Amphotericin B; Miltefosine; Paromomycin; Sitamaquine; Sodium stibogluconate; Visceral leishmaniasis

Indexed keywords

ALLOPURINOL; AMBISONE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; FLUCONAZOLE; GAMMA INTERFERON; IMMUNOMODULATING AGENT; ISOQUINOLINE DERIVATIVE; KETOCONAZOLE; LICOCHALCONE A; MILTEFOSINE; PAMIDRONIC ACID; PAROMOMYCIN; PENTAMIDINE ISETHIONATE; PYRROLE DERIVATIVE; RISEDRONIC ACID; SITAMAQUINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ACUTE KIDNEY TUBULE NECROSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLACTIC SHOCK; ANTIFUNGAL ACTIVITY; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOTOXICITY; CHILL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; ELECTROLYTE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; KIDNEY DYSFUNCTION; MIXED INFECTION; MYOCARDITIS; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOPHLEBITIS; VISCERAL LEISHMANIASIS; VOMITING;

EID: 63349107346     PISSN: None     EISSN: 11781181     Source Type: Journal    
DOI: 10.4137/cpath.s821     Document Type: Article

References (19)

1. Bora D. Epidemiology of leishmania in India. National Medical Journal of India. 1999;12:62-68.
2. Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem. 2007;14:1153-69.
3. Sundar S. Drug resistance in Indian Visceral leishmaniasis Tropical Medicine and International Health. 2001;6:849-54.
4. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr Pharm Des. 2002;8:319-42.
5. Thakur CP, Sinha GP, Pandey AK. Comparison of regimens of amphotericin deoxycholate in kala-azar. Indian Journal of Medical Research. 1996;103:259-63.
6. Sundar S, Agrawa, G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomized trial. British Medical Journal. 323, 419-22.
7. Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ. Randomized control trial of aminosidine (Paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in north Bihar, India. British Medical Journal.1998;316:1200-5.
8. Croft SL, Seifert K, Duchêne M. Antiprotozoal activities of phospholipid analogues. Mol Biochem Parasitol. 2003;126:165-72.
9. Sundar S, Chatterjee M. Visceral leishmaniasis - current therapeutic modalities. Indian Journal of Medical Research. 2006;123:345-52.
10. Jha TK, Sundar S, Thakur, CP, Felton JM, Sabin, AJ and Horton, J. A phase-II dose-rating study of Sitamaquine for the treatment of visceral leishmaniasis in India. American Journal of Tropical Medicine and Hygiene. 2005;73:1005-11.
11. Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian Journal of Medical Research. 2006;123:399-410.
12. Murray HW. Treatment of visceral leishmaniasis in 2004. American Journal of Tropical Medicine and Hygiene. 2004;71:787-94.
13. Thakur CP, Sinha PK, Singh RK, Hassan SM, Narain S. Miltefosine in a case of visceral leishmaniasis with HIV co-infection and rising incidence of this disease in India. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2000;94:696-7.
14. Sindermann H, Engel KR, Fischer C, Bommer W. Miltefosine Compassionate Use Program. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clinical Infectious Diseases. 2004;39:1520-3.
15. Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis. 2006;43:1371-2.
16. Thakur CP, Kanyok PP, Pandey AK, Sinha GP, Zaniewsai AE, Haulihan HH. A prospective randomized comparative open lable trial of the safety and efficacy of paromomycin plus sodium stibogluconate v sodium stibogluconate alone for the treatment of visceral leishmaniasis. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2000;94:429-31.
17. Jha TK, Singh NKP, Singh IJ, Combination therapy in kala-azar. Journal of Association of Physicians of India. 1995;43:319-20.
18. Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon gamma plus pentavalent antimony in Indian visceral leishmaniasis. Journal of Infectious Diseases. 1997;176:1117-9.
19. Pandey K, Sinha PK, Das VNR, et al. HIV-1 infection, visceral leishmaniasis, Koch's chest and tuberculous meningitis in the same patient - a case report. Annals of Tropical Medicine and Parasitology. 2005;99:807-11.